Application of AKRIB10 combined with GPC-3 in immunohistochemical diagnosis of hepatocellular carcinoma
10.3724/SP.J.1008.2012.00625
- Author:
Guang-zhi JIN
1
Author Information
1. Department of Pathology, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University
- Publication Type:Journal Article
- Keywords:
Aldo-keto reductase family 1;
Diagnosis;
Glypican 3;
Hepatocellular carcinoma;
Immunohistochemistry;
Member B10
- From:
Academic Journal of Second Military Medical University
2012;33(6):625-628
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the value of AKRIBIO combined with GPC-3 in improving the sensitivity and specificity of immunohistochemical diagnosis of hepatocellular carcinoma (HCC). Methods The microarray including 75 HCC and adjacent tissues was subjected to immunohistochemistry detection of AKRIBIO and GPC-3 expression. A Logistic regression diagnostic model was established using the results of tissue microarray (training group). The ROC curves (the receiver-operating characteristic curve) and area under the curve (AUC) were used to evaluate the sensitivity and specificity of AKRIBIO, GPC-3 or their combination. The Logistic regression diagnostic model was validated with 200 HCC and adjacent tissues (testing group). Results For the training group, the AUC values of AKRIBIO, GPC-3, and AKRIBIO combined with GPC-3 were 0. 773, 0. 800, and 0. 931, respectively. The sensitivity of AKRIBIO and GPC-3 were 56% and 61. 3%, respectively, and their specificity was both 98. 7%. AKRIBIO combined with GPC-3 yielded a sensitivity of 88. 0% and a specificity of 97. 3%. For the testing group, sensitivity and specificity of AKRIBIO combined with GPC-3 were 97. 0% and 96. 5%, respectively. Conclusion AKRIBIO combined with GPC-3 can greatly improve the sensitivity and specificity of HCC immunohistochemical diagnosis, and it should be used when necessary in addition to the routine pathological assessment.
